<DOC>
	<DOCNO>NCT00515411</DOCNO>
	<brief_summary>Chemotherapy give together standard way treat cancer . One standard treatment include combination docetaxel , cisplatin , fluorouracil . However , original combination three drug cause many side effect . This study do find three drug give low dos often , few side effect still maintain benefit standard way give three drug combination . If tumor overexpresses protein call Her2 , also eligible receive trastuzumab chemotherapy . Trastuzumab medicine approve US Food Drug Administration treatment Her2 positive breast cancer . Trastuzumab also standard treatment combination chemotherapy treatment Her2 positive stomach cancer . If tumor Her2 positive , would receive modified administration schedule docetaxel , cisplatin , fluorouracil trastuzumab .</brief_summary>
	<brief_title>Study Modified Docetaxel , Cisplatin , Fluorouracil ( mDCF ) Unresectable Metastatic Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients must histologically cytologically confirm metastatic unresectable gastric gastroesophageal junction ( GEJ ) adenocarcinoma . GEJ adenocarcinoma may classify accord Siewert 's classification type I , II , III [ 43 ] . Histological documentation local recurrence metastasis strongly encourage , unless risk procedure outweigh potential benefit confirm metastatic disease . If histologic confirmation , metastases recurrence require documentation 2nd radiographic procedure ( eg . PET/CT scan MRI addition CT scan ) . If imaging procedure confirm recurrent metastatic disease , biopsy confirmation require . Patients must disease evaluate radiographically . This may measurable disease nonmeasurable disease . Measurable disease define measure least one dimension &gt; 20 mm conventional technique , &gt; 10 mm high resolution image . Disease identify radiology study , meet criterion measurable disease , consider nonmeasurable . Patients may receive prior chemotherapy metastatic unresectable disease . Patients may receive prior adjuvant therapy ( chemotherapy and/or chemoradiation ) 6 month elapse end adjuvant therapy registration . Patients may receive prior docetaxel cisplatin . Age 18 year old . Karnofsky performance status &gt; = 70 % ( ECOG performance status 01 ) . Peripheral neuropathy &lt; = grade 1 . Hematologic ( minimal value ) : White blood cell count &gt; = 3000/mm3 Absolute neutrophil count &gt; = 1500 cells/ mm3 Hemoglobin &gt; = 9.0 g/dl Platelet count &gt; = 100,000 / mm3 Hepatic ( minimal value ) : Total bilirubin &lt; = 1.5 * * AST ALT Alkaline phosphatase must within eligible range . In determine eligibility , abnormal two value ( AST ALT ) use . Patients alkaline phosphatase elevation secondary bony metastasis rather liver dysfunction may proceed treatment protocol discussion principal investigator . Kidney function ( minimal value ) : * Serum creatinine &lt; = 1.5 mg/dl serum creatinine 1.21.5 mg/dl , creatinine clearance ( either measure calculate ) must 50 ml/min great The patient PT ( INR ) &lt; = 1.5 PTT &lt; = 3 second upper limit normal patient anticoagulation . If patient fulldose anticoagulant , follow criterion meet enrollment : The patient must inrange INR ( usually 2 3 ) stable dose warfarin stable dose LMW heparin The patient must active bleed pathological condition carry high risk bleeding ( e.g . tumor involve major vessel , know varix ) Women childbearing potential negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Ability understand inform consent sign write informed consent document prior initiation protocol therapy . Patients must HER2positive ( FISH+ IHC 3+ ) metastatic unresectable gastric gastroesophageal junction ( GEJ ) adenocarcinoma eligible trastuzumab . For purpose protocol , FISH+ define HER2 : CEP17 ratio ≥ 2.0 . Biopsy sample cohesive IHC3+ FISH+ clone consider HER2 positive irrespective size , i.e. &lt; 10 % . FISH+ define &gt; 2 HER2 : CEP17 . Patients receive trastuzumab must leave ventricular ejection fraction ≥ 50 % . Patients receive previous chemotherapy treatment metastatic unresectable gastric GEJ adenocarcinoma ineligible . Patients receive previous pre postoperative chemotherapy chemoradiation ineligible therapy complete less 6 month prior study registration . Patients must recover adverse event previous therapy . Patients receive previous docetaxel cisplatin . Patients history another neoplastic disease within past three year , exclude basal cell carcinoma skin , cervical carcinoma situ , nonmetastatic prostate cancer . Patients brain central nervous system metastasis , include leptomeningeal disease . Pregnant ( positive pregnancy test ) breast feeding . Serious , nonhealing wound , ulcer , bone fracture . Significant cardiac disease define : unstable angina , New York Heart Association ( NYHA ) grade II great , congestive heart failure , history myocardial infarction within 6 month Evidence bleed diathesis coagulopathy . History stroke CVA within 6 month Clinically significant peripheral vascular disease . Clinically significant hearing loss ring ear . Patients history severe hypersensitivity reaction Taxotere® drug formulate polysorbate 80 . Inability comply study and/or followup procedure . Patients medical condition reason , investigator 's opinion , make patient unstable participate clinical trial . For patient Her2 positive treat trastuzumab + mDCF cohort , prior trastuzumab treatment allow . For patient Her2 positive treat trastuzumab+mDCF cohort , leave ventricular function &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>gastroesophageal junction</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>unresectable gastric cancer</keyword>
	<keyword>metastatic gastric</keyword>
</DOC>